• LAST PRICE
    1.0048
  • TODAY'S CHANGE (%)
    Trending Down-0.0152 (-1.4902%)
  • Bid / Lots
    0.9910/ 4
  • Ask / Lots
    1.0100/ 12
  • Open / Previous Close
    1.0000 / 1.0200
  • Day Range
    Low 0.9911
    High 1.0200
  • 52 Week Range
    Low 0.5004
    High 8.6100
  • Volume
    16,749
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.02
TimeVolumeKZIA
09:32 ET7101.02
09:55 ET1101.0164
10:09 ET1001.0169
10:20 ET31001.01
10:58 ET4001.005
11:00 ET1501.005
11:02 ET4001.005
11:14 ET1001.0038
11:16 ET13701
11:25 ET71431.01
12:08 ET12990.9912
12:14 ET11000.9912
12:17 ET1001.0048
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKZIA
Kazia Therapeutics Ltd
16.8M
-0.8x
---
United StatesQNRX
Quoin Pharmaceuticals Ltd
12.3M
0.0x
---
United StatesATHE
Alterity Therapeutics Ltd
17.2M
-0.2x
---
United StatesADIL
Adial Pharmaceuticals Inc
12.3M
-0.6x
---
United StatesONCR
Oncorus Inc
11.7M
-0.2x
---
United StatesVRPX
Virpax Pharmaceuticals Inc
12.4M
-0.6x
---
As of 2023-02-03

Company Information

Kazia Therapeutics Limited is an Australia-based oncology-focused biotechnology company. The Company is engaged in pharmaceutical research and development. The Company’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer. The Company’s lead programs include paxalisib and EVT801. Paxalisib is a small molecule, brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 is being developed in patients with advanced cancer. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor.

Contact Information

Headquarters
Three International Towers Level 24 , 300 Barangaroo AvenueSYDNEY, NSW, Australia 2000
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Iain Ross
Chief Executive Officer, Executive Director
James Garner
Chief Financial Officer
Karen Krumeich
Chief Medical Officer
John Friend
Clinical & Regulatory Affairs Manager
Lilischkis Kimberley

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$16.8M
Revenue (TTM)
$1.5K
Shares Outstanding
18.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.10
EPS
$-1.32
Book Value
$0.95
P/E Ratio
-0.8x
Price/Sales (TTM)
11,332.8
Price/Cash Flow (TTM)
---
Operating Margin
-1,191,709.00%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.